Stock market analysts have maintained 'buy' rating on Exide Industries Ltd with an intraday target of Rs 310.

According to them, interested traders can purchase the stock above Rs 304 with a strict stop loss of Rs 300.

If the bourses remain on the positive track, then the stock price will hit a target above Rs 315.

Shares of the company, on Wednesday (Nov 11), closed at Rs 304.75 on the Bombay Stock Exchange (BSE). The share price has seen a 52-week high of Rs 302.50 and a low of Rs 162 on BSE. Current EPS & P/E ratio of the stock stood at 12.91 & 23.89 respectively.

Mumbai-based drug manufacturer Cipla has announced the launching of generic versions of anti-flu medicines oseltamivir and zanamivir in the market for the treatment of Swine flu, which is spreading all through the world.

Cipla has rolled out oseltamivir under the brand name 'Antiflu' and zanamivir as 'Virenza'.

Antiflu will be priced at Rs 475 (10 capsules), in proportion to the cost of rival products in the market. Virenza, which is an inhaled drug, will be available at a cost of Rs 800.

Both the medicines, used internationally to deal the unending H1N1 epidemic, lack patent protection in India as these are pre-1995 inventions. Such inventions are not granted patent rights in the Indian market, as per the product patent rule launched in India since 2005.

Cipla has recorded an 82% growth in its quarterly income profit owing to higher sales.

Cipla's net profit for the quarter ended Sep 30 stood at Rs 276 as against Rs 151 crore in thhe same period of the last year.

During the period, the company witnessed a growth of 5.27% in its net sales, which stood at Rs 1,371 crore.